Ratings Johnson & Johnson Buenos Aires S.E.

Equities

JNJD

ARDEUT110236

End-of-day quote Buenos Aires S.E. Other stock markets 03:30:00 28/05/2024 am IST			5-day change	1st Jan Change
9.84 ^USD	-1.60%		-4.93%	-3.53%

28/05	Sector Update: Health Care Stocks Fall Late Afternoon	MT
28/05	Sector Update: Health Care Stocks Retreat Tuesday Afternoon	MT

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The company's enterprise value to sales, at 3.85 times its current sales, is high.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
JOHNSON & JOHNSON	-3.53%	347B	-
ELI LILLY AND COMPANY	+38.59%	727B	C+
MERCK & CO., INC.	+15.66%	319B	B-
ABBVIE INC.	+0.24%	274B	C+
ASTRAZENECA PLC	+13.47%	238B	B+
NOVARTIS AG	+7.35%	204B	B-
ROCHE HOLDING AG	-6.42%	203B	A+
AMGEN INC.	+4.23%	161B	C+
PFIZER, INC.	-1.70%	160B	C+
SANOFI	-1.31%	120B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes